D. Boral Capital Reaffirms “Buy” Rating for Invivyd (NASDAQ:IVVD)

D. Boral Capital reissued their buy rating on shares of Invivyd (NASDAQ:IVVD) in a research note published on Thursday morning,Benzinga reports. D. Boral Capital currently has a $9.00 price objective on the stock.

IVVD has been the subject of several other research reports. Morgan Stanley decreased their price objective on Invivyd from $9.50 to $3.55 and set an “overweight” rating for the company in a research note on Wednesday, November 20th. HC Wainwright decreased their price objective on Invivyd from $15.00 to $10.00 and set a “buy” rating for the company in a research note on Wednesday, November 20th. Finally, EF Hutton Acquisition Co. I upgraded Invivyd to a “strong-buy” rating in a research note on Wednesday, October 30th. Four investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company. According to data from MarketBeat, the stock has an average rating of “Buy” and an average target price of $7.89.

Invivyd Stock Performance

Shares of IVVD opened at $0.72 on Thursday. The stock has a 50-day simple moving average of $0.97 and a 200-day simple moving average of $1.22. The stock has a market capitalization of $86.57 million, a PE ratio of -0.36 and a beta of 0.65. Invivyd has a 1 year low of $0.69 and a 1 year high of $5.20.

Institutional Investors Weigh In On Invivyd

Several institutional investors have recently added to or reduced their stakes in the business. Vanguard Group Inc. lifted its stake in Invivyd by 3.9% during the first quarter. Vanguard Group Inc. now owns 2,611,202 shares of the company’s stock worth $11,594,000 after purchasing an additional 97,496 shares during the last quarter. State Street Corp increased its position in Invivyd by 3.7% during the third quarter. State Street Corp now owns 1,018,640 shares of the company’s stock worth $1,039,000 after buying an additional 35,904 shares during the period. Marshall Wace LLP increased its position in Invivyd by 4.2% during the second quarter. Marshall Wace LLP now owns 786,899 shares of the company’s stock worth $866,000 after buying an additional 31,992 shares during the period. Acadian Asset Management LLC increased its position in Invivyd by 232.0% during the second quarter. Acadian Asset Management LLC now owns 678,706 shares of the company’s stock worth $745,000 after buying an additional 474,301 shares during the period. Finally, Duquesne Family Office LLC acquired a new position in Invivyd during the second quarter worth approximately $629,000. Hedge funds and other institutional investors own 70.36% of the company’s stock.

About Invivyd

Invivyd, Inc, a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of antibody-based solutions for infectious diseases in the United States. The company developed INVYMAB, a platform that combines viral surveillance and predictive modeling with advanced antibody engineering.